Carr Douglas has filed a Form 144 to sell 266 shares of Century Therapeutics, Inc., a move that highlights ongoing activity within the biotechnology sector.

This filing, submitted on November 3, 2026, is significant as it demonstrates Douglas's recent acquisition of the shares through restricted stock vesting.

Background

Carr Douglas is associated with Century Therapeutics, Inc., which operates in the biological products industry. The company is incorporated in Delaware and is listed under the SEC file number 001-40498. Century Therapeutics focuses on innovative therapies in the biotechnology field.

What the Filing Says

The filing states that Douglas sold 266 shares of Century Therapeutics, with an aggregate market value of $403.94. The shares were sold on November 3, 2026, and were acquired the day before through a restricted stock vesting transaction.

Impact

This transaction may affect other stakeholders in Century Therapeutics, particularly investors and market participants who closely monitor insider trading activities. The filing indicates that Douglas has been active in selling shares, with previous sales reported in August and September 2026.

What's Next

The filing does not say what happens next.

Additional Details

Carr Douglas's recent sale of 266 shares is part of a broader trend of insider transactions at Century Therapeutics. Notably, in the three months leading up to this filing, Douglas sold a total of 2,187 shares across multiple transactions, with gross proceeds amounting to approximately $4,265.07. The previous sales included 275 shares on August 3, 2026, for $543.73, 254 shares on September 8, 2026, for $520.57, and 1,658 shares on September 14, 2026, for $3,200.77.

The filing also indicates that the recent sale was partly to cover tax obligations resulting from the settlement of a vested equity award distribution, highlighting the financial planning involved in such transactions.

Brokerage Information

The shares were sold through Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI. This brokerage is responsible for executing the transaction on behalf of Douglas, who is identified as an officer of Century Therapeutics in the filing.

Company Overview

Century Therapeutics, Inc. is focused on developing innovative therapies in the biological products sector, specifically within the realm of cellular therapies. The company is incorporated in Delaware and operates under the SEC file number 001-40498. Its fiscal year ends on December 31, and it is headquartered in Philadelphia, PA.

Market Context

While the filing provides insight into Douglas's transactions, it does not include any information on the current market conditions affecting Century Therapeutics or the biotechnology sector at large. Additionally, there are no details regarding any upcoming corporate events or announcements that may impact the company's stock performance or insider trading activities.